The stock of Allogene Therapeutics Inc. (NASDAQ:ALLO) last traded at $4.58, down -1.08% from the previous session.
Data from the available sources indicates that Allogene Therapeutics Inc. (NASDAQ:ALLO) is covered by 19 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $6.00, we find $15.00. Given the previous closing price of $4.63, this indicates a potential upside of 223.97 percent. ALLO stock price is now -17.43% away from the 50-day moving average and -38.57% away from the 200-day moving average. The market capitalization of the company currently stands at $669.37M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 3 analysts have assigned it a hold rating, and 14 have given it a buy rating. Brokers who have rated the stock have averaged $16.91 as their price target over the next twelve months.
In other news, Bhavnagri Veer, General Counsel sold 3,000 shares of the company’s stock on Feb 13. The stock was sold for $20,550 at an average price of $6.85. Upon completion of the transaction, the General Counsel now directly owns 577,677 shares in the company, valued at $2.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17, General Counsel Bhavnagri Veer sold 3,000 shares of the business’s stock. A total of $21,120 was realized by selling the stock at an average price of $7.04. This leaves the insider owning 580,677 shares of the company worth $2.66 million. Insiders disposed of 153,232 shares of company stock worth roughly $0.7 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALLO stock. A new stake in Allogene Therapeutics Inc. shares was purchased by BAKER BROS. ADVISORS LP during the first quarter worth $7,222,000. UBS ASSET MANAGEMENT AMERICAS INC invested $2,442,000 in shares of ALLO during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Allogene Therapeutics Inc. valued at approximately $1,992,000. INTEGRAL HEALTH ASSET MANAGEMENT, LLC acquired a new stake in ALLO for approximately $1,855,000. JEFFERIES FINANCIAL GROUP INC. purchased a new stake in ALLO valued at around $1,814,000 in the second quarter. In total, there are 259 active investors with 76.20% ownership of the company’s stock.
With an opening price of $4.6200 on Thursday morning, Allogene Therapeutics Inc. (NASDAQ: ALLO) set off the trading day. During the past 12 months, Allogene Therapeutics Inc. has had a low of $4.30 and a high of $17.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.10, and a quick ratio of 8.10. The fifty day moving average price for ALLO is $5.5472 and a two-hundred day moving average price translates $7.4558 for the stock.
The latest earnings results from Allogene Therapeutics Inc. (NASDAQ: ALLO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.68, missing analysts’ expectations of -$0.62 by -0.06. This compares to -$0.56 EPS in the same period last year. The company reported revenue of $52000.0 for the quarter, compared to $61000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -14.75 percent. For the current quarter, analysts expect ALLO to generate $20k in revenue.
Allogene Therapeutics Inc.(ALLO) Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
